Received Apr 7, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 273H3 | IM / LL |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | Z006283 | IM / RL |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | Z015168 | SC / LL |
Patient is a 13-months old Male, presenting to the clinic today with parents for acute visit. Patient has been seen by the ED/Urgent Care for this concern prior to appointment. Seen on 03/30/26 at EACH for rash. Follow-up visit with PCM on 4/1/26: Suspect varicella most likely. Consulted with Dr (name withheld) (hospitalist). Dr (name withheld): plan: "As it is greater than 24 hours since onset, acyclovir unlikely to be beneficial in a patient that is otherwise well-appearing. Recommend supportive treatment at preventing scratching and superinfection with staph or strep species. Consider cetirizine for baseline pruritus control with breakthrough diphenhydramine as needed. Keep lesions moist with Aquaphor. Cleared to return to daycare once all lesions have crusted over/scabbed over. Reviewed results of my discussion with Dr. (name withheld) as well as treatment recommendations with NP (name withheld). Additionally, recommend stopping cephalexin as this would potentially select out for more virulent/antibiotic resistant staph and/or strep species should this child go on to develop cellulitis or deeper tissue infection." Discussed these recommendations with parents and voiced understanding. Daycare return precautions also discussed with parents Return precautions discussed but inform staff immediately upon arrival of suspected issue.
ear infection
none
vitamin D 400units per day
No known allergies
No labs, parent declined